Ken Griffin Cardiff Oncology, Inc. Transaction History

Citadel Advisors LLC

$483 Billion
Q2 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Cardiff Oncology, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 23,900 shares of CRDF stock, worth $60,706. This represents 0.0% of its overall portfolio holdings.

Number of Shares

23,900

Previous 26,500 9.81%

Holding current value

$60,706

Previous $141,000 62.41%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$2.22 - $5.89 $123,867 - $328,638	55,796 New	55,796 $123,000
Q4 2023 Feb 14, 2024	BUY	$0.96 - $1.55 $26,649 - $43,028	27,760 New	27,760 $41,000
Q2 2023 Aug 14, 2023	BUY	$1.37 - $1.95 $108,388 - $154,276	79,116 Added 1129.1%	86,123 $126,000
Q1 2023 May 15, 2023	BUY	$1.45 - $2.09 $1,871 - $2,698	1,291 Added 22.59%	7,007 $11,000
Q4 2022 Feb 14, 2023	SELL	$1.22 - $1.66 $237,343 - $322,943	-194,544 Reduced 97.15%	5,716 $8,000
Q3 2022 Nov 14, 2022	BUY	$1.54 - $3.21 $108,975 - $227,149	70,763 Added 54.64%	200,260 $308,000
Q2 2022 Aug 15, 2022	SELL	$1.17 - $2.61 $553,386 - $1.23 Million	-472,980 Reduced 78.51%	129,497 $285,000
Q1 2022 May 16, 2022	BUY	$2.11 - $7.25 $924,926 - $3.18 Million	438,354 Added 267.09%	602,477 $1.49 Million
Q4 2021 Feb 14, 2022	SELL	$5.18 - $7.24 $3.69 Million - $5.16 Million	-712,525 Reduced 81.28%	164,123 $986,000
Q3 2021 Nov 15, 2021	SELL	$5.01 - $7.58 $1.54 Million - $2.33 Million	-306,902 Reduced 25.93%	876,648 $5.84 Million
Q2 2021 Aug 16, 2021	SELL	$6.65 - $10.04 $768,181 - $1.16 Million	-115,516 Reduced 8.89%	1,183,550 $7.87 Million
Q1 2021 May 17, 2021	BUY	$9.1 - $19.57 $3.93 Million - $8.46 Million	432,101 Added 49.84%	1,299,066 $12 Million
Q4 2020 Feb 16, 2021	BUY	$12.02 - $24.71 $8.54 Million - $17.6 Million	710,854 Added 455.35%	866,965 $15.6 Million
Q3 2020 Nov 16, 2020	BUY	$4.25 - $14.19 $663,471 - $2.22 Million	156,111 New	156,111 $2.22 Million

Others Institutions Holding CRDF

# of Institutions

Shares Held

12.8M

Call Options Held

823K

Put Options Held

78K

View Full List

About Cardiff Oncology, Inc.

Ticker CRDF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,334,900
Market Cap $110M
Description
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...

More about CRDF

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account